Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


Weight Gain During HIV Treatment and the Latest in HIV Prevention

March 8-11, 2020; Boston, Massachusetts
Hear insights from Monica Gandhi, MD, MPH, on new data reported at CROI 2020 related to weight gain and other metabolic changes during HIV antiretroviral therapy (ART) as well as new information on HIV prevention strategies.
Monica Gandhi, MD, MPH
Released: June 5, 2020

Podcast Notes

In this episode, Dr. Gandhi discusses topline results from several studies investigating weight gain and metabolic outcomes with different antiretroviral therapy (ART) regimens among patients with HIV, including lipid level changes, cardiovascular disease risk, diabetes risk, and metabolic syndrome risk. The overview will include analyses from:

  • The ADVANCE trial comparing initial ART with DTG plus FTC/TAF, DTG plus FTC/TDF, or EFV/FTC/TDF, including an examination of the influence of CYP2B6 polymorphisms on weight change during EFV-based therapy
  • The NA-ACCORD study
    • Evaluating patients with virologic suppression who switched from non–integrase inhibitor (INSTI)–based regimens to INSTI-based regimens
    • Investigating the impact of initial ART regimen class on diabetes mellitus incidence
  • A study investigating the association between resting metabolic rate, oxygen consumption, and dietary intake changes and body weight/composition changes following ART initiation
  • A study evaluating differences in postpartum weight change with DTG-based vs EFV-based ART

In addition, Dr. Gandhi reviews new information on biomedical prevention of HIV infection, including results from several preclinical trials, a study investigating real-time urine-based testing for tenofovir levels, and the latest safety data from the phase III DISCOVER trial comparing FTC/TDF vs FTC/TAF for daily oral HIV pre-exposure prophylaxis (PrEP) among cis-gender men who have sex with men (MSM) and transgender women.

Content based on an online CME program supported by independent educational grants from Gilead Sciences; Merck & Co., Inc.; and ViiV Healthcare.

Link to full program: https://www.clinicaloptions.com/hiv/conference-coverage/retroviruses-2020

Information on this Educational Activity


Monica Gandhi, MD, MPH

Professor of Medicine
Division of HIV, Infectious Diseases, and Global Medicine
University of California, San Francisco
Medical Director
Ward 86 HIV Clinic
San Francisco General Hospital
San Francisco, California

Monica Gandhi, MD, MPH, has no relevant conflicts of interest to report.


Jennifer Blanchette, PhD

Senior Scientific Director

Jennifer Blanchette, PhD, has no relevant conflicts of interest to report.
Edward King, MA

Executive Vice President

Edward King, MA, has no relevant conflicts of interest to report.

Program Medium

This program has been made available online.

Related Content

Video of panel discussion on ending the US HIV epidemic with Drs. Michelle Cespedes, Monica Gandhi, and David Wohl from CCO HIV annual meeting

Expert CCO commentary from Dr. Gregory Huhn, reviewing current data on PrEP innovations to prevent HIV infection

Gregory Huhn, MD, MPHTM Released: October 27, 2020

Expert selections of the most important new data from HIV Glasgow 2020, including current and investigational ART, and more, from CCO

Monica Gandhi, MD, MPH Renslow Sherer, MD Released: October 23, 2020

Renslow Sherer, MD, discusses new HIV data reported at the HIV Glasgow 2020 Virtual Conference, in the CCO Infectious Disease podcast

Renslow Sherer, MD Released: October 22, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.